IGM Historical Income Statement
IGMS Stock | USD 10.04 0.39 3.74% |
Historical analysis of IGM Biosciences income statement accounts such as Interest Expense of 8.3 M or Selling General Administrative of 27 M can show how well IGM Biosciences performed in making a profits. Evaluating IGM Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of IGM Biosciences's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining IGM Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IGM Biosciences is a good buy for the upcoming year.
IGM |
About IGM Income Statement Analysis
IGM Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to IGM Biosciences shareholders. The income statement also shows IGM investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
IGM Biosciences Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of IGM Biosciences. It is also known as IGM Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on IGM Biosciences income statement and represents the costs associated with goods and services IGM Biosciences provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from IGM Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into IGM Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IGM Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.At this time, IGM Biosciences' Income Tax Expense is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 17.7 M in 2024, whereas Gross Profit is likely to drop (6.5 M) in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 4.5M | 6.1M | 8.0M | 8.4M | Total Operating Expenses | 165.3M | 229.0M | 265.6M | 278.9M |
IGM Biosciences income statement Correlations
Click cells to compare fundamentals
IGM Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
IGM Biosciences income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 597K | 1.0M | 4.5M | 6.1M | 8.3M | 8.7M | |
Selling General Administrative | 9.2M | 18.3M | 38.3M | 49.7M | 50.1M | 27.0M | |
Gross Profit | (22.6M) | (3.6M) | (7.7M) | 1.1M | (6.1M) | (6.5M) | |
Other Operating Expenses | 44.5M | 83.3M | 165.3M | 229.0M | 265.6M | 278.9M | |
Operating Income | (44.5M) | (83.3M) | (165.3M) | (228.0M) | (263.5M) | (250.3M) | |
Net Income From Continuing Ops | (43.1M) | (81.4M) | (165.2M) | (221.1M) | (238.3M) | (226.4M) | |
Ebit | (44.5M) | (83.3M) | (165.3M) | (228.0M) | (261.6M) | (248.6M) | |
Research Development | 35.3M | 65.0M | 127.0M | 179.3M | 215.5M | 226.3M | |
Ebitda | (43.9M) | (82.3M) | (160.8M) | (221.9M) | (253.4M) | (240.7M) | |
Cost Of Revenue | 22.6M | 3.6M | 7.7M | 10.6M | 8.3M | 8.0M | |
Total Operating Expenses | 44.5M | 83.3M | 165.3M | 229.0M | 265.6M | 278.9M | |
Reconciled Depreciation | 597K | 1.0M | 4.5M | 6.1M | 8.0M | 8.4M | |
Income Before Tax | (43.1M) | (81.4M) | (165.2M) | (221.1M) | (245.7M) | (233.5M) | |
Total Other Income Expense Net | 1.4M | 1.9M | 159K | 6.9M | 17.7M | 18.6M | |
Net Income Applicable To Common Shares | (43.1M) | (81.4M) | (165.2M) | (221.1M) | (199.0M) | (189.0M) | |
Net Income | (42.5M) | (80.3M) | (160.7M) | (214.2M) | (246.4M) | (234.1M) | |
Income Tax Expense | (597K) | (1.0M) | (4.5M) | (6.9M) | 678K | 711.9K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.